Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PNP | P00491 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8839875 | 0.96 | POLB (0.45) | POLBNPC1CNR2TSHRGAA | |
| SCHEMBL28594973 | 0.82 | PNP (0.53) | POLBNPC1CNR2TSHRGAA | |
| SCHEMBL618073 | 0.82 | PNP (0.53) | POLBNPC1CNR2TSHRGAA | |
| SCHEMBL18002191 | 0.81 | TRPA1 (0.46) | POLBNPC1CNR2TSHRKMT2A | |
| SCHEMBL15530737 | 0.80 | TSHR (0.43) | POLBCNR2TSHRGAAKMT2A | |
| SCHEMBL7880359 | 0.80 | PNP (0.44) | POLBNPC1TSHRGAAKMT2A | |
| SCHEMBL6227253 | 0.79 | POLB (0.54) | POLBNPC1CNR2TSHRGAA | |
| SCHEMBL21936369 | 0.78 | POLB (0.53) | POLBNPC1CNR2TSHRGAA | |
| Hydrochloric Acid SCHEMBL29101371 | 0.78 | POLB (0.49) | POLBNPC1CNR2TSHRGAA | |
| Glycerin SCHEMBL27987155 | 0.78 | CNR2 (0.46) | POLBCNR2TSHRGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| EP-2200656-B1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2012-12-05 | — | — | EP | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8323619-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-12-04 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-8202511-B2 | Contrast agents | GE HEALTHCARE AS (NO) | 2012-06-19 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| US-20100303734-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2010-12-02 | — | — | US | disclosed |
| EP-2200656-A1 | CONTRAST AGENTS | GE Healthcare AS (NO) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071605-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009060021-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-05-14 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| WO-2009047319-A1 | CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2009-04-16 | — | — | WO | disclosed |
| EP-0675105-B1 | Polyiodinated compounds, process for their preparation and diagnostic composition | GUERBET SA (FR) | 1998-12-23 | — | — | EP | disclosed |
| US-5693311-A | Polyiodinated compounds, process for preparing them and diagnostic compositions | GUERBET S.A. (FR) | 1997-12-02 | — | — | US | disclosed |
| EP-0675105-A1 | Polyiodinated compounds, process for their preparation and diagnostic composition | GUERBET S.A. (FR) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100303734-A1 | CONTRAST AGENTS | C1R, CNKSR1, C5 | POLB 2890/4885NPC1 615/4885CNR2 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.